Search

The aim of the study was to evaluate acute side effects after extremely hypofractionated intensity-modulated radiotherapy (IMRT) with stereotactic body radiation therapy (SBRT) for definitive treatment of prostate cancer patients.

Purpose The aim of this study was to compare the dosimetry of intraoperative dose plans of prostate cancer patients treated with low-dose–rate (LDR) and high-dose–rate (HDR) interstitial brachytherapy (BT). Methods and Materials A randomized clinical trial was initiated at our institution to compare the results and side effects of LDR and HDR BT as monotherapy in the treatment of early, organ-confined prostate cancer patients. Eighty-seven patients were randomly assigned to receive HDR afterloading BT with one fraction of 19 Gy or permanent LDR 125 I seed BT with 145 Gy. Inverse optimization algorithms were used for planning. Stranded seeds were implanted using live ultrasound imaging after preimplant treatment planning. Final dosimetry of HDR treatments was based on updated needle and contour positions. Statistical comparisons with nonparametric test were performed between the corresponding dose–volume parameters. Results The V 100 and V 150 were 99% and 61%, respectively, for LDR, whereas 98% and 32% for HDR treatments. The D 90 was less for HDR (122% vs. 110%). The dose distributions were more homogeneous and conformal with HDR technique (dose homogeneity index, 0.39 vs. 0.67; conformal index, 0.65 vs. 0.80). The urethra and rectum received significantly less dose with HDR. The D 10 and D 30 for urethra were 133% and 128%, respectively, for LDR and 114% and 111% for HDR treatments. The D 2 cm 3 for rectum was 68% and 55% for LDR and HDR technique, respectively. Conclusions Both techniques provided acceptable target volume coverage with a slightly higher value with the LDR technique. The dose distributions were more homogeneous and conformal, and both urethra and rectum were better protected with the HDR technique. [ABSTRACT FROM AUTHOR]

Poster: Physics track: Treatment planning: applications PO-1494: Dose integration method of intensitymodulated arc therapy and HDR brachytherapy of prostate cancer G. Fröhlich, P. à goston, K. Jorgo, C. Polgár, T. Major. [Extracted from the article]